CXCR4 and neoplasm: We have recently demonstrated that the innate resistance of metastatic ovarian tumors in syngeneic mice could be overcome by an oncolytic vaccinia virus-delivered CXCR4 antagonist (OV-CXCR4-A)9 by reducing tumor load and the immunosuppressive network, leading to intratumoral accumulation of CD8+ T cells and increased overall survival compared with tumor-bearing mice treated with control viruses.10